Received by email:

File: NR15Jan2015EmpiricalLabs.doc

ABATTIS ANNOUNCES A MANUFACTURING PARTNERSHIP 
WITH EMPIRICAL LABS OF FT. COLLINS, COLORADO

Vancouver, BC - January 15, 2015 - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CSE: ATT
--->), a specialty biotechnology company focused on cultivating, licensing and marketing proprietary ingredients, bio-simi
--->lar compounds, equipment and consulting services to North American medicinal markets, today announces a manufacturing 
--->partnership with Empirical Labs., of Ft. Collins, Colorado 
This relationship will allow Abattis Bioceuticals Corp the exclusive license for Cannabidiol rich hemp oil products de
--->livered directly to licensed physicians and dispensaries. 
Empirical Labs is a high quality nutraceutical manufacturing facility. They specialize in Liposomal delivery of nutrie
--->nts, a process that improves the absorption of phytochemicals by binding them to beneficial fats. This process will in
--->crease the delivery of phytocannabinoids in Abattis Cannabidiol-rich hemp oil from 50% to 90%. 
In 1989, Herbalists Kelly and Nazreen Goyen started Empirical Labs. As natural health enthusiasts they used their own 
--->experiences in healing to help shape Empirical Labs. Their work towards providing high quality nutraceutical products 
--->for doctors and consumers quickly earned them a reputation as having a keen sense of quality when selecting herbs, ext
--->racts, vitamins and minerals.
Empirical Labs is managed by Clinical Herbalist, Asa Waldstein who is an American Herbalist Guild member and honors gr
--->aduate of The Rocky Mountain Center for Botanical Studies (Paul Bergner/Feather Jones). Asa possesses extensive herbal
---> wildcrafting and formulation knowledge and has over 15 years experience managing in the natural products industry.
Dr. Emek Blair Ph.D. oversees our R & D and Quality Assurance. He earned his undergraduate degree from Occidental Coll
--->ege and performed his graduate work in bio-analytical Chemistry at the University of California, Irvine. Dr. Blair dev
--->eloped the proprietary and cutting edge liposome technology used at Empirical Labs to formulate and manufacture its hi
--->ghly effective liposomal product line.
 About Abattis Bioceuticals Corp.
Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, l
--->icensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to m
--->edicinal markets in North America. The Company is positioned to capitalize on the fast growing trend toward marijuana 
--->legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and pa
--->rtnering with companies to employ its mass cultivation systems, extraction equipment/technology, and strategic marketi
--->ng support to licensed growers. The Company also has an extensive pipeline of high-quality products and intellectual p
--->roperty for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to 
--->the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.aba
--->ttis.com.
ON BEHALF OF THE BOARD
"Mike Withrow" Michael Withrow, President & CEO
For further information, contact Saf Dhillon, IR for Abattis Bioceuticals Corp. at (604) 568-8868 or at news@abattis.c
--->om.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY 
--->FOR THE ADEQUACY ORACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimat
--->e", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-l
--->ooking statements. Although the Company believes that the expectations and assumptions on which the forward-looking st
--->atements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the C
--->ompany can give no assurance that they will prove to be correct. Since forward-looking statements address future event
--->s and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as o
--->f the date of this press release. Actual results could differ materially from those currently anticipated due to a num
--->ber of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under th
--->e Company's profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information
---> at any particular time.